Healthcare Equipment and Supplies
Company Overview of Cordis Corporation
Cordis Corporation, through its subsidiaries, develops, manufactures, and distributes drug-eluting stents, catheters, and guide wires for interventional medicine, minimally invasive computer-based imaging, and electrophysiology applications. The company offers a portfolio of access, diagnostic, and interventional medical products for use in cardiovascular, endovascular, and biliary duct (liver) obstructive interventional procedures. Its cardiology products include transradial solutions for radial access procedures; diagnostic products, such as access kits, sheath introducers, diagnostic guide wires, and diagnostic catheters; guiding and PTCA dilatation catheters; and steerable guide wires an...
430 Route 22 East
Bridgewater, NJ 08807
Founded in 1959
Key Executives for Cordis Corporation
Vice President of Worldwide Clinical Research & Operations
Chief Scientific Officer and Global Head of Research & Development
Vice President of Regulatory Affairs and Quality Assurance
Vice President of Latin American Operations
Vice President of Corporate Relations and Assistant Secretary
Compensation as of Fiscal Year 2014.
Cordis Corporation Key Developments
Cordis Corporation Launches INCRAFT(R) AAA Stent Graft System for Treatment of Abdominal Aortic Aneurysms (AAA)
Sep 10 14
Cordis Corporation announced the launch of its INCRAFT(R) AAA Stent Graft System (INCRAFT(R) System), an ultra-low profile device for use during endovascular aneurysm repair (EVAR) for patients suffering from infrarenal abdominal aortic aneurysms (AAA). The INCRAFT(R) System is cleared for use and now available in Europe and Canada. This device is an advancement in the EVAR field and provides a new option for patients and physicians seeking a less invasive treatment approach for AAA. An estimated 24 million people worldwide suffer from AAA, an abnormal enlargement of the large blood vessel (aorta) that supplies blood to the abdomen, pelvis and legs. Left untreated, all aneurysms will eventually rupture and the majority of ruptured aneurysms result in death. The INCRAFT(R) System is intended for the endovascular treatment of patients with infrarenal AAA. The INCRAFT(R) System, which features an ultra-low profile endovascular stent graft system with innovative technology designed for durability, conformability and sealing without the need for polymers, is intended to reinforce the lower part of the aorta to prevent an aneurysm from rupturing. The INCRAFT(R) System is the lowest profile EVAR system now available in Europe and Canada with a 14 French (F) outer diameter, including the integrated sheath, which is equivalent to a 12F catheter sheath introducer profile. Most EVAR stent grafts have a system profile ranging from 16F to 22F in size. This ultra-low profile device is designed for proximal and distal placement accuracy and allows for customization during the procedure to accommodate a wide range of anatomical sizes. This broad anatomical coverage is offered with a minimal number of product codes for easier pre-procedural planning. The INNOVATION Trial is a multicenter, open-label, prospective, non-randomized study designed to assess the safety and performance of the device in the treatment of patients with AAA with investigational sites in Germany and Italy. At two years, results from the study demonstrated the device performed well in patients and showed no incidences of aneurysm enlargement, endoleaks (type I, or III), device or procedure related major adverse events, stent-graft migrations or stent fractures. One patient in the study developed a late graft occlusion unrelated to the device that was caused by shrinkage of the aneurysm. The two-year study results were presented at the 2014 Charing Cross Symposium and subsequently published in the July 2014 online issue of the Journal of Vascular Surgery. The INCRAFT(R) System is currently approved for investigational device use only in the U.S. and Japan and is being studied in a global pivotal clinical study in the U.S. and Japan called the INSPIRATION Trial, which completed enrollment in 2013.
Johnson & Johnson Reportedly Plans To Shed Cordis
Sep 1 14
Johnson & Johnson (NYSE:JNJ) reportedly intends to dispose of its medical devices unit Cordis Corporation. A potential sale which is currently in its early stages could bring between $1.5 billion and $2 billion. The unit was expected to attract bids from private equity players and rival healthcare companies.
Cordis Corporation Launches SABER(TM) PTA Dilatation Catheter to Complement Portfolio of Peripheral Arterial Disease Treatments
Jul 1 14
Cordis Corporation announced the launch of its SABER(TM) PTA Dilatation Catheter for the treatment of patients with Peripheral Arterial Disease (PAD). The SABER(TM) Catheter is cleared for use and now available in Europe, the United States and Japan. This new CORDIS(R) product offers outstanding crossability and a comprehensive offering of balloon sizes on the widely-used 0.018" over-the-wire platform. Physicians can now treat a wider range of PAD patients with a single balloon brand. Developed to complement the CORDIS(R) PTA portfolio as a next-generation, high-performance workhorse 0.018" PTA balloon catheter, SABER(TM) Catheter is intended to dilate stenoses in iliac, femoral, ilio-femoral, popliteal, infrapopliteal and renal arteries and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. The device is also indicated for post-dilation of balloon-expandable and self-expanding stents in the peripheral vasculature. SABER(TM) Catheter is available in balloon diameters of 2-10mm and lengths of 20-300mm. SABER(TM) Catheter combines a durable dual layer hydrophilic coating with a low-profile body and new molded tip design to enhance crossability. The catheter has exceptional rated burst pressures of up to 18 atm due to its construction with trusted DURALYN(R) Material.
Similar Private Companies By Industry
Recent Private Companies Transactions